Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 3 art units • 4 examiners • 0 of 8 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Axsome Therapeutics Inc. has 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 4 distinct examiners, which indicates that examiners are managing multiple cases for the company on average. HOWELL, THEODORE R is the busiest examiner, currently overseeing 5 pending office actions.
This means that a single examiner is responsible for a majority of the 8 pending office actions in the portfolio. The activity is concentrated within 3 distinct art units. For practitioners, the high concentration of 5 pending office actions with HOWELL, THEODORE R makes this examiner the primary focus for the company's current prosecution efforts.
The workload is distributed such that the other 4 distinct examiners handle the remaining actions. With only 3 distinct art units involved, the technical scope of the pending office actions is relatively focused. Success in the portfolio is heavily dependent on the interactions with the busiest examiner across the cases he manages.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| Double-patenting only | 3 (38%) |
| Double-patenting + other | 1 (12%) |
| No statute on record | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, THEODORE R | 5 | 66.8% | +25.3% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
| THOMAE, EVAN GODFREY | 1 | — | — |
| BREDEFELD, RACHAEL EVA | 1 | 27.4% | +35.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19236838 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 77d overdue |
| 19169261 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 67d overdue |
| 18366992 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 44d overdue |
| 18503996 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 19d |
| 18512551 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 26d |
| 19079284 | PHARMACEUTICAL COMPOSITIONS COMPRISING UNIFORM BLENDS OF REBOXETINE | YOUNG, MICAH PAUL | — |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | — |
| Art Unit | Apps |
|---|---|
| 1628 | 5 |
| 1618 | 1 |
| 3786 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19236838 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | §103 | Non-Final OA | 77d overdue | Pending | Jun 12, 2025 |
| 19169261 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | 67d overdue | Pending | Apr 03, 2025 |
| 19079284 | PHARMACEUTICAL COMPOSITIONS COMPRISING UNIFORM BLENDS OF REBOXETINE | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | — | Pending | Mar 13, 2025 |
| 18950743 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | THOMAE, EVAN GODFREY | — | §103§112DP | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | 3786 | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
| 18512551 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | DP | Final Rejection | 26d | Pending | Nov 17, 2023 |
| 18503996 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | DP | Final Rejection | 19d | Pending | Nov 07, 2023 |
| 18366992 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | DP | Final Rejection | 44d overdue | Pending | Aug 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial